Mühlbäck, Alžbeta http://orcid.org/0000-0002-0385-3071
Mana, Josef
Wallner, Michael
Frank, Wiebke
Lindenberg, Katrin S.
Hoffmann, Rainer
Klempířová, Olga
Klempíř, Jiří
Landwehrmeyer, G. Bernhard
Bezdicek, Ondrej
,
Funding for this research was provided by:
EU Joint Programme – Neurodegenerative Disease Research (Project Nr. 8F19004)
Univerzita Karlova v Praze (Grant PROGRES Q27/LF1)
Rare Diseases Clinical Research Network (Project ID No 739510)
Universität Ulm
Article History
Received: 3 February 2023
Revised: 13 June 2023
Accepted: 14 June 2023
First Online: 22 June 2023
Declarations
:
: A.M, K.L., R.H., J.K., G.B.L: their institutions have received compensation for clinical trial services from the following companies: Hoffmann-La Roche, Novartis, Prilenia, Wave and the CHDI Foundation Non-financial support (travel and accommodation reimbursement) from European Huntington’s Disease Network. W.F, M.W., O.B, O.K.; J.M.: nothing to disclose.
: This study was based on the anonymous data set extracted from the periodic data set 4 (PDS4) of the Enroll-HD study. Enroll-HD was approved by the local institutional ethical review boards at every study site and conducted in accordance with the ethical standards described in the Declaration of Helsinki of 1964. All participants provided written informed consent for their participation.